Industry
Biotechnology
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Loading...
Open
9.74
Mkt cap
1.2B
Volume
1.7M
High
10.09
P/E Ratio
-7.06
52-wk high
10.09
Low
9.62
Div yield
N/A
52-wk low
1.79
Portfolio Pulse from Benzinga Newsdesk
September 19, 2024 | 3:41 pm
Portfolio Pulse from Benzinga Newsdesk
September 19, 2024 | 3:30 pm
Portfolio Pulse from Benzinga Newsdesk
September 19, 2024 | 1:01 pm
Portfolio Pulse from Avi Kapoor
September 19, 2024 | 12:24 pm
Portfolio Pulse from Avi Kapoor
September 18, 2024 | 6:31 pm
Portfolio Pulse from Avi Kapoor
September 18, 2024 | 4:12 pm
Portfolio Pulse from Surbhi Jain
September 18, 2024 | 3:22 pm
Portfolio Pulse from Vandana Singh
September 18, 2024 | 2:52 pm
Portfolio Pulse from Avi Kapoor
September 18, 2024 | 1:57 pm
Portfolio Pulse from Benzinga Newsdesk
September 18, 2024 | 12:27 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.